The Times reported that a medicine called raloxifene that is usually prescribed to treat brittle bones has been shown to prevent invasive breast cancer. The study has found that raloxifene that often helps to prevent and treat osteoporosis significantly reduces the risk of developing invasive breast cancers. In this case the word significantly means by more than 50%. The action of this medication is based on binding to oestrogen receptors in the body. It appeared during the study that by doing this raloxifene is able to prevent some of the effects of oestrogen that spur cancer growth.

This large study provides supportive evidence for the hypothesis that was previously made by scientists: raloxifene could potentially reduce the occurrence of oestrogen-receptor positive breast cancer. Though the researchers concluded that raloxifene decreases the risk of invasive oestrogen-receptor positive breast cancer in postmenopausal women regardless of any underlying risk factors that they have, it is unknown yet which role could raloxifene play in prevention of breast cancer.

Archives of Internal Medicine reported in its Junes issue that men with lower levels of vitamin D in the body refer to higher risk group of heart atta...

The US Food and Drug Administration warns consumers throughout the USA not to eat any kind of raw red tomatoes. This warning was expanded because the...